BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 30249388)

  • 1. HIV-Specific, Ex Vivo Expanded T Cell Therapy: Feasibility, Safety, and Efficacy in ART-Suppressed HIV-Infected Individuals.
    Sung JA; Patel S; Clohosey ML; Roesch L; Tripic T; Kuruc JD; Archin N; Hanley PJ; Cruz CR; Goonetilleke N; Eron JJ; Rooney CM; Gay CL; Bollard CM; Margolis DM
    Mol Ther; 2018 Oct; 26(10):2496-2506. PubMed ID: 30249388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effects of Human Immunodeficiency Virus Type 1 (HIV-1) Antigen-Expanded Specific T-Cell Therapy and Vorinostat on Persistent HIV-1 Infection in People With HIV on Antiretroviral Therapy.
    Gay CL; Hanley PJ; Falcinelli SD; Kuruc JD; Pedersen SM; Kirchherr J; Raines SLM; Motta CM; Lazarski C; Chansky P; Tanna J; Shibli A; Datar A; McCann CD; Sili U; Ke R; Eron JJ; Archin N; Goonetilleke N; Bollard CM; Margolis DM
    J Infect Dis; 2024 Mar; 229(3):743-752. PubMed ID: 38349333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy.
    Deeks SG; Wagner B; Anton PA; Mitsuyasu RT; Scadden DT; Huang C; Macken C; Richman DD; Christopherson C; June CH; Lazar R; Broad DF; Jalali S; Hege KM
    Mol Ther; 2002 Jun; 5(6):788-97. PubMed ID: 12027564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of HIV replication in the resting CD4+ T cell reservoir by autologous CD8+ T cells: implications for the development of therapeutic strategies.
    Chun TW; Justement JS; Moir S; Hallahan CW; Ehler LA; Liu S; McLaughlin M; Dybul M; Mican JM; Fauci AS
    Proc Natl Acad Sci U S A; 2001 Jan; 98(1):253-8. PubMed ID: 11136258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expanded cytotoxic T-cell lymphocytes target the latent HIV reservoir.
    Sung JA; Lam S; Garrido C; Archin N; Rooney CM; Bollard CM; Margolis DM
    J Infect Dis; 2015 Jul; 212(2):258-63. PubMed ID: 25589335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of Latent HIV-1 T Cell Reservoirs with a Combination of Innate Immune and Epigenetic Regulators.
    Palermo E; Acchioni C; Di Carlo D; Zevini A; Muscolini M; Ferrari M; Castiello L; Virtuoso S; Borsetti A; Antonelli G; Turriziani O; Sgarbanti M; Hiscott J
    J Virol; 2019 Nov; 93(21):. PubMed ID: 31413127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Residual HIV-specific CD4 and CD8 T cell frequencies after prolonged antiretroviral therapy reflect pretreatment plasma virus load.
    Oxenius A; Price DA; Dawson SJ; Günthard HF; Fischer M; Perrin L; Ramirez E; Fagard C; Hirschel B; Scullard G; Weber JN; McLean AR; Phillips RE;
    AIDS; 2002 Nov; 16(17):2317-22. PubMed ID: 12441804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between CD38 expression on peripheral blood T-cells and monocytes, and response to antiretroviral therapy: a one-year longitudinal study of a cohort of chronically infected ART-naive HIV-1+ patients.
    Almeida M; Cordero M; Almeida J; Orfao A
    Cytometry B Clin Cytom; 2007 Jan; 72(1):22-33. PubMed ID: 17051525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling HIV-1 Latency Using Primary CD4
    Takata H; Kessing C; Sy A; Lima N; Sciumbata J; Mori L; Jones RB; Chomont N; Michael NL; Valente S; Trautmann L
    J Virol; 2019 Jun; 93(11):. PubMed ID: 30918072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autologous IgG antibodies block outgrowth of a substantial but variable fraction of viruses in the latent reservoir for HIV-1.
    Bertagnolli LN; Varriale J; Sweet S; Brockhurst J; Simonetti FR; White J; Beg S; Lynn K; Mounzer K; Frank I; Tebas P; Bar KJ; Montaner LJ; Siliciano RF; Siliciano JD
    Proc Natl Acad Sci U S A; 2020 Dec; 117(50):32066-32077. PubMed ID: 33239444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4
    Madrid-Elena N; García-Bermejo ML; Serrano-Villar S; Díaz-de Santiago A; Sastre B; Gutiérrez C; Dronda F; Coronel Díaz M; Domínguez E; López-Huertas MR; Hernández-Novoa B; Moreno S
    J Virol; 2018 May; 92(9):. PubMed ID: 29444937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Spontaneous Control of HIV-1 Is Related to Low Frequency of Infected Cells and Inefficient Viral Reactivation.
    Noel N; Peña R; David A; Avettand-Fenoel V; Erkizia I; Jimenez E; Lecuroux C; Rouzioux C; Boufassa F; Pancino G; Venet A; Van Lint C; Martinez-Picado J; Lambotte O; Sáez-Cirión A; Prado JG
    J Virol; 2016 Jul; 90(13):6148-6158. PubMed ID: 27122576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype.
    Sáez-Cirión A; Lacabaratz C; Lambotte O; Versmisse P; Urrutia A; Boufassa F; Barré-Sinoussi F; Delfraissy JF; Sinet M; Pancino G; Venet A;
    Proc Natl Acad Sci U S A; 2007 Apr; 104(16):6776-81. PubMed ID: 17428922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reactivation Kinetics of HIV-1 and Susceptibility of Reactivated Latently Infected CD4+ T Cells to HIV-1-Specific CD8+ T Cells.
    Walker-Sperling VE; Cohen VJ; Tarwater PM; Blankson JN
    J Virol; 2015 Sep; 89(18):9631-8. PubMed ID: 26178987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vorinostat Renders the Replication-Competent Latent Reservoir of Human Immunodeficiency Virus (HIV) Vulnerable to Clearance by CD8 T Cells.
    Sung JA; Sholtis K; Kirchherr J; Kuruc JD; Gay CL; Nordstrom JL; Bollard CM; Archin NM; Margolis DM
    EBioMedicine; 2017 Sep; 23():52-58. PubMed ID: 28803740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Harnessing CD8
    Warren JA; Clutton G; Goonetilleke N
    Front Immunol; 2019; 10():291. PubMed ID: 30863403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication.
    Tebas P; Jadlowsky JK; Shaw PA; Tian L; Esparza E; Brennan AL; Kim S; Naing SY; Richardson MW; Vogel AN; Maldini CR; Kong H; Liu X; Lacey SF; Bauer AM; Mampe F; Richman LP; Lee G; Ando D; Levine BL; Porter DL; Zhao Y; Siegel DL; Bar KJ; June CH; Riley JL
    J Clin Invest; 2021 Apr; 131(7):. PubMed ID: 33571163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD8+ cell anti-HIV activity rapidly increases upon discontinuation of early antiretroviral therapy.
    Killian MS; Roop J; Ng S; Hecht FM; Levy JA
    J Clin Immunol; 2009 May; 29(3):311-8. PubMed ID: 19189205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD38 expression on CD8 T cells has a weak association with CD4 T-cell recovery and is a poor marker of viral replication in HIV-1-infected patients on antiretroviral therapy.
    Steel A; John L; Shamji MH; Henderson DC; Gotch FM; Gazzard BG; Kelleher P
    HIV Med; 2008 Feb; 9(2):118-25. PubMed ID: 18257774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy.
    Liu B; Zou F; Lu L; Chen C; He D; Zhang X; Tang X; Liu C; Li L; Zhang H
    J Virol; 2016 Nov; 90(21):9712-9724. PubMed ID: 27535056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.